Friday, December 16, 2011

Synta's ganetespib shows potent in vitro and in vivo activity against multiple breast cancer types

Synta researchers  have reported that, Ganetespib (structure)  shows potent in vitro and in vivo activity against multiple types of breast cancer including HER2-positive, ER/PR positive, triple-negative, and inflammatory breast cancer. 

"These results demonstrating that ganetespib potently inhibits key signaling pathways involved in the growth and proliferation of multiple forms of breast cancer are encouraging, and supportive of the results presented earlier at this meeting showing single-agent, anti-tumor activity in patients with breast cancer who have progressed on or failed to respond to multiple prior therapies," said Vojo Vukovic, M.D., Ph.D., Chief Medical Officer, Synta. 

Researchers conclude that, the combined preclinical and clinical results create a strong rationale for advancing ganetespib development in both HER2-positive and triple-negative breast cancer.

More : http://phoenix.corporate-ir.net/phoenix.zhtml?c=147988&p=irol-newsArticle&ID=1638540&highlight=

No comments: